Opposing results of the monarchE and PALLAS trials investigating the role of adjuvant treatment with the CDK4/6 inhibitors abemaciclib and palbociclib, respectively, in patients with hormone receptor-positive, HER2-negative early stage breast cancer have recently been presented. Herein, potential reasons why these two drugs that have similar efficacy in the metastatic setting have produced disparate results in the adjuvant setting are discussed.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925–1936 (2016).
Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926–1936 (2018).
Sledge, G. W. Jr et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875–2884 (2017).
Sledge, G. W. Jr et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy — MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116–124 (2020).
Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638–3646 (2017).
Hortobagyi, G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med. 375, 1738–1748 (2016).
Slamon, D. J. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl. J. Med. 382, 514–524 (2020).
Johnston, S. R. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J. Clin. Oncol. https://doi.org/10.1200/JCO.20.02514 (2020).
Mayer, E. L. et al. LBA12 – PALLAS: a randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2− early breast cancer [abstract]. Ann. Oncol. 31(Suppl. 4), S1142–S1215 (2020).
Pfizer Inc. PENELOPE-B trial of ibrance® (palbociclib) in early breast cancer did not meet primary endpoint https://www.pfizer.com/news/press-release/press-release-detail/penelope-b-trial-ibrancer-palbociclib-early-breast-cancer (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.C. has advisory roles with AstraZeneca, Bristol-Myers Squibb, Daichii Sankyo, Lilly, Novartis, Pfizer, Roche, Seagen and Veracyte.
Rights and permissions
About this article
Cite this article
Curigliano, G. CDK4/6 inhibitors for HR+HER2− early stage breast cancer — when to escalate treatment?. Nat Rev Clin Oncol 18, 67–68 (2021). https://doi.org/10.1038/s41571-020-00453-1
Published:
Issue date:
DOI: https://doi.org/10.1038/s41571-020-00453-1
